2024-09-08 - Analysis Report
## AMGN Stock Analysis Report

**Company Overview:** Amgen Inc. is a leading biotechnology company that develops, manufactures, and markets innovative human therapeutics.

**Performance Analysis:**

1. **Performance vs. S&P 500:** 
    * AMGN's cumulative return is **51.95%**, while the S&P 500 (VOO) has returned **81.34%**.
    * This results in a **-29.39%** difference, meaning AMGN has underperformed the market.
    * The relative underperformance is at **48.09%**, which means it's performing at the 48th percentile of its historical performance against the S&P 500. 

2. **Recent Price Movement:**
    * **Closing Price:** 320.56
    * **5-day Moving Average:** 327.98
    * **20-day Moving Average:** 326.43
    * **60-day Moving Average:** 322.86
    * The stock is currently below all three moving averages, indicating a potential downtrend.

3. **Technical Indicators:**
    * **RSI:** 48.88 -  Suggests the stock is neither overbought nor oversold, but currently in a neutral position.
    * **PPO:** -0.19 - A negative PPO indicates a potential downtrend, consistent with the moving average observations.
    * **Delta_Previous_Relative_Divergence:** -6.04 - A negative value suggests a recent decrease in relative performance compared to the S&P 500. 
    * **Expected Return:** 7.27% - A relatively low expected return, which is the maximum potential 5-year return based on current investment.

4. **Recent Earnings and Outlook:**
    | Date | EPS | Revenue |
    |---|---|---|
    | 2024-08-07 | 1.39 | 8.39 B$ |
    | 2024-05-03 | -0.21 | 7.45 B$ |
    | 2023-10-31 | 3.23 | 6.90 B$ |
    | 2023-08-04 | 2.58 | 6.99 B$ |
    | 2024-08-07 | 2.58 | 6.99 B$ |

    The most recent earnings report (2024-08-07) showed EPS of 1.39, exceeding analyst expectations. Revenue was also higher than expected. However, the recent earnings beat might not be enough to offset the long-term underperformance compared to the market. 

**Conclusion:**

AMGN has been underperforming the S&P 500 in the long term, and its recent price movement suggests a potential downtrend. Although the most recent earnings report was positive, the long-term outlook remains uncertain. Technical indicators suggest a neutral position, but the negative Delta_Previous_Relative_Divergence and low Expected Return indicate caution.  Overall, while the company has a strong position in the biotechnology sector, its current performance raises concerns for investors. 
